Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XB0T
|
|||
| Former ID |
DNCL002602
|
|||
| Drug Name |
Acolbifene
|
|||
| Synonyms |
Acolbifene; EM-652; 182167-02-8; UNII-815LJ9X0D1; 815LJ9X0D1; EM 652; Acolbifene [INN:BAN]; SCH 57068; AC1L4EAA; SCHEMBL406183; CHEMBL68055; CTK4F5320; SCH-57068; HY-16023A; ( )-(2S)-3-(4-Hydroxyphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-1-benzopyran-7-ol; CS-0007143; (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-7-ol; (S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-chromen-7-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 3 | [1] | |
| Company |
EndoCeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H31NO4
|
|||
| Canonical SMILES |
CC1=C(C(OC2=C1C=CC(=C2)O)C3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O
|
|||
| InChI |
1S/C29H31NO4/c1-20-26-14-11-24(32)19-27(26)34-29(28(20)21-5-9-23(31)10-6-21)22-7-12-25(13-8-22)33-18-17-30-15-3-2-4-16-30/h5-14,19,29,31-32H,2-4,15-18H2,1H3/t29-/m0/s1
|
|||
| InChIKey |
DUYNJNWVGIWJRI-LJAQVGFWSA-N
|
|||
| CAS Number |
CAS 182167-02-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01452373) Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women. U.S. National Institutes of Health. | |||
| REF 2 | Bioactivation of the selective estrogen receptor modulator acolbifene to quinone methides. Chem Res Toxicol. 2005 Feb;18(2):174-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.